2 results
Approved WMOPending
To evaluate the safety and efficacy of ravagalimab vs placebo for the treatment of primary Sjogren's syndrome (pSS) in subjects with moderately to severely active primary Sjogren's syndrome (pSS).
Approved WMOPending
Primary objective:* To compare the rates of complete recovery (alive, free of dialysis and return of serum creatinine to <150% of reference baseline; equivalent to acute kidney disease (AKD) category 0) at Day 14 between the Reltecimod-…